Huadong Pharmaceutical announced that on July 31, the company and its subsidiaries participated in the 12th batch of centralized procurement bids for state-organized drugs. Ciclosporin softgels, tacrolimus capsules, and mesalazine enteric tablets will be selected. The total sales revenue in 2025 is about 2,076 billion yuan, accounting for 4.76% of that year's revenue. Four products, including isaconazole injections, were not selected. The total sales revenue for 2025 was about 4.634 billion yuan, accounting for 10.62% of that year's revenue. The company has formulated plans to deal with collection pressure, and the innovative R&D pipeline layout has been expanded to more than 90 projects. It is expected that more than 40 innovative products will be launched in stages over the next five years. The purchase agreement for the products to be selected has not been signed, and there is uncertainty.

Huadong Pharmaceutical announced that on July 31, the company and its subsidiaries participated in the 12th batch of centralized procurement bids for state-organized drugs. Ciclosporin softgels, tacrolimus capsules, and mesalazine enteric tablets will be selected. The total sales revenue in 2025 is about 2,076 billion yuan, accounting for 4.76% of that year's revenue. Four products, including isaconazole injections, were not selected. The total sales revenue for 2025 was about 4.634 billion yuan, accounting for 10.62% of that year's revenue. The company has formulated plans to deal with collection pressure, and the innovative R&D pipeline layout has been expanded to more than 90 projects. It is expected that more than 40 innovative products will be launched in stages over the next five years. The purchase agreement for the products to be selected has not been signed, and there is uncertainty.